FDA Approves TOFACITINIB CITRATE — ScieGen Pharmaceuticals, INC.

ScieGen Pharmaceuticals has received FDA approval for its generic version of Tofacitinib Citrate, potentially intensifying price competition in the oral immunosuppressant market. This launch comes at a moment of increasing sector consolidation, challenging market share for established brands and influencing access for patients managing complex rheumatoid conditions.